Abstract:Objective: The purpose of this study was to determine whether serum fms-like tyrosine kinase 1 (sFlt1) concentration during preeclampsia were associated with mid trimester blood pressure, other maternal characteristics, or pregnancy outcomes. Study design: We performed a nested case-control study within the Calcium for Preeclampsia Prevention study cohort. Each woman with preeclampsia (case) was matched to 1 normotensive control. A total of 120 pairs of women was chosen randomly. Serum concentrations of sFlt1 and placental growth factor were measured throughout pregnancy, but before labor and delivery. We focused on data from 40 women with blood specimens that were obtained after the onset of preeclampsia. After logarithmic transformation, we determined mean serum sFlt1 concentrations of all control specimens within gestational age windows during which case specimens had been obtained after the onset of preeclampsia. Within each of these gestational age windows, we computed an upper bound for the control specimens equal to 2 standard deviations above the mean. After the onset of preeclampsia, 16 women with log-transformed serum sFlt1 values greater than the upper bound of the control specimens were considered to have high preeclampsia serum sFlt1 levels. The 24 other women were considered to have low preeclampsia serum sFlt1 levels. Results: Women with high or low concentrations of serum sFlt1 during preeclampsia (arithmetic means, 5746 and 3007 pg/mL, respectively) had similar pregnancy outcomes and similar maternal characteristics, except for blood pressure at Calcium for Preeclampsia Prevention study enrollment. Systolic and diastolic blood pressure at enrollment at 13 to 21 weeks of gestation were significantly higher in the 24 women with low serum sFlt1 concentrations during preeclampsia (systolic blood pressure, 114 mm Hg; diastolic blood pressure, 65 mm Hg) than in the 16 women who had preeclampsia at high serum sFlt1 concentrations (systolic blood pressure, 106 mm Hg; diastolic blood pressure, 59 mm Hg). Blood pressure at 13 to 21 weeks among the women with high preeclampsia serum sFlt1 concentrations was identical to the blood pressure among normotensive control subjects. In linear regression analyses of data from all 40 women, both systolic (P < .0001) and diastolic (P = .014) blood pressures at enrollment were correlated negatively with natural logarithm serum sFlt1 concentration after onset of preeclampsia. Conclusion: Women with higher mid trimester blood pressure had preeclampsia at lower serum sFlt1 concentrations. Because higher blood pressure may reflect occult endothelial damage, these observations may explain increased susceptibility to preeclampsia among women with pre-existing vascular disease.

Levels of Serum Hoxb3 and Sflt‐1 in Pre‐eclamptic Patients and Their Effects on Pregnancy Outcomes

The Expression of Serum Segfr, Sflt-1, Sendoglin and PLGF in Preeclampsia

Alterations of maternal serum and placental follistatin-like 3 and myostatin in pre-eclampsia.

Serum Adiponectin, Leptin and Soluble Leptin Receptor in Pre-Eclampsia.

Changes of Serum Pregnancy-Associated Plasma Protein-A,Placental Growth Factor and Solu-ble Fms-Like Tyrosine Kinase Receptor-1 Concentrations in Preeclampsia Patients

Serum and Placental Interleukin-18 Are Elevated in Preeclampsia

Reduced Expression of Follicle Stimulating Hormone Receptor Mrna and Protein in Pregnancies Complicated by Pre-Eclampsia

Serum Preadipocyte Factor-1 is Increased in Fetuses of Pregnancy Complicated with Severe Preeclampsia.

Study on the Relation Between Concentration of Circulating Non-Host Fetal DNA in Pregnant Women and Pre-Eclampsia

Value of a ratio of sFlt-1 to PLGF in prospecting the preeclampsia

Clinical Usefulness of Soluble Fms-Like Tyrosine Kinase 1, Soluble Endoglin and Placental Growth Factor in Korean Women with Preeclampsia

The expression of imprinted genes IGF 2 and PHLDA 2 in mid-pregnancy have predictive values for the development of pre-eclampsia

Serum Levels of Complement Factors C1q, Bb, and H in Normal Pregnancy and Severe Pre-Eclampsia

The value of serum angiogenic factors for predicating development of preeclampsia

Expression of Matrix Metalloproteinase-2,-7,-9 in Serum During Pregnancy in Patients with Pre-Eclampsia: A Prospective Study

The Hcg Levels in Maternal Serum and Human Placentas on Hypertensive Disorders Complicating Pregnancy

Clinical Validation of the sFlt-1:PlGF Ratio as a Biomarker for Preeclampsia Diagnosis in a High-Risk Obstetrics Unit

Inconformity of CXCL3 Plasma Level and Placenta Expression in Preeclampsia and Its Effect on Trophoblast Viability and Invasion

Expression and significance of soluble fms-like tyrosine kinase-1 in preeclampsia

Serum sFlt1 concentration during preeclampsia and mid trimester blood pressure in healthy nulliparous women

Serum Protein Marker Panel for Predicting Preeclampsia.